Kopran Limited — Q3 FY25 earnings call

Call held 25 Mar 2025

Management summary

Kopran Limited announced the Board approval for the merger of Kopran Laboratories Limited on March 20, 2025. This strategic move aims to integrate Kopran Limited into the rapidly growing Indian diagnostic market, leveraging synergies to become a comprehensive healthcare company. Kopran Laboratories, valued at INR 256 crores, operates on a robust annuity-based model, targeting 28-30% EBITDA margins, and has demonstrated significant growth, with its FY24 top line increasing by 45% to INR 103 crores. The merger is anticipated to be EPS accretive and enhance shareholder value.

Highlights

  • Merger expected to be EPS accretive to Kopran Limited and create value for shareholders.

  • Entry into the fast-growing Indian diagnostic industry, projected to reach $25 billion by FY28 with a 14% CAGR.

  • Kopran Laboratories' strong growth trajectory, with FY24 top line increasing by approximately 45% to INR 103 crores.

  • Kopran Laboratories operates on an annuity-type business model, with approximately 50% of its top line derived from long-term contracted business.

  • Management targets an EBITDA margin of 28-30% for Kopran Laboratories, indicating healthy profitability.

Concerns

  • Kopran Laboratories' 9-month revenue for the current year (INR 68-69 crores) appeared broadly muted compared to its full FY24 revenue (INR 103 crores), though management clarified this is due to Q4 seasonality.

Key financials

4 periods

Headline

  • Kopran Labs EBITDA Margin
    29%
  • Kopran Labs Valuation
    ₹256 Cr

9M FY24

  • Kopran Labs Revenue
    ₹59 Cr

9M FY25

  • Kopran Labs Revenue
    ₹68.5 Cr
    YoY +16.1%

FY24

  • Kopran Labs Revenue
    ₹103 Cr
    YoY +45%

What they filed

Q1 FY27: revenue up 22.3%, net profit up 90.9% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue74 72 76 51 42 −42%94 +30%118 +55%63 +22%
EBITDA10 11 12 5 -3 −133%18 +55%27 +116%8 +67%
Net profit7 7 9 4 -4 −160%12 +64%19 +118%7 +91%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Capital allocation

high confidence
  • Capex ₹7 Cr entirely through internal accruals
    • Adding 20-25 diagnostic machines annually ₹7 Cr
    And we expect this 20 to 25 machine investment, which is typically around INR7 crores to INR8 crores to happen every year. This is all funded by internal accruals. Like Sanjayji mentioned, we are sitting on a decent amount of cash in the company. So that takes care of any such capex requirements.
  • M&A Kopran Laboratories Limited Merger · Pending regulatory · AUM ₹256 Cr

    To create synergy by leveraging strengths, exploit health care and diagnostic market, entry into fast-growing Indian diagnostic industry, EPS accretive, and create value for shareholders.

    EPS accretive to Kopran Limited.

    The proposed share exchange ratio is 100 fully paid up equity shares of Kopran Limited against 45 fully paid up equity shares of Kopran Laboratories Limited after receiving all the regulatory approvals... Kopran Lab was valued at about INR256 crores and at about INR25 crores of cash, so about INR230 crores.
  • Liquidity Liquidity disclosed Kopran Limited is sitting on a decent amount of cash, which will fund Kopran Laboratories' capex requirements.
    Like Sanjayji mentioned, we are sitting on a decent amount of cash in the company. So that takes care of any such capex requirements.

Guidance & targets

Market Growth

  • Indian Diagnostic Industry Growth Market Growth · next 5 years · High confidence 14% CAGR
    The merger will give Kopran an entry into the fast-growing $14 billion Indian diagnostic industry, which is growing at a CAGR of 14% over the next 5 years and is expected to almost double and reach $25 billion in FY '28 and nearly threefold by 2034.

    — Surendra Somani

Market Size

  • Indian Diagnostic Industry Size Market Size · FY28 · High confidence $25 billion
    The merger will give Kopran an entry into the fast-growing $14 billion Indian diagnostic industry, which is growing at a CAGR of 14% over the next 5 years and is expected to almost double and reach $25 billion in FY '28 and nearly threefold by 2034.

    — Surendra Somani

Profitability

  • Kopran Labs EBITDA Margin Profitability · ongoing · High confidence 28-30%
    So typically, we would like to we would work with -- EBITDA margin is around 28% to 30%.

    — Varun Somani

Capex

  • Kopran Labs Annual Machine Additions Capex · every year · High confidence 20-25 machines
    And every year, we typically add 20 to 25 machines.

    — Varun Somani

  • Kopran Labs Annual Capex Capex · every year · High confidence INR 7-8 crores
    And we expect this 20 to 25 machine investment, which is typically around INR7 crores to INR8 crores to happen every year.

    — Varun Somani

Revenue

  • Kopran Labs Q4 FY25 Performance Revenue · Q4 FY25 · Medium confidence very big quarter
    So similarly, this year as well, we expect that Q4 will be a very big quarter for us as compared to the previous quarters.

    — Varun Somani

What to watch in Q4 FY25

Kopran Labs Q4 FY25 Performance

next quarter (Q4 FY25 results)
Current 9M FY25 revenue at INR 68-69 crores, Q4 expected to be 'very big'.
Target Strong Q4 revenue growth, contributing significantly to annual performance.

Why it matters

Management emphasized Q4 seasonality; strong performance will validate their business model and merger rationale.

So our last quarter was close to a INR43 crores quarter. So similarly, this year as well, we expect that Q4 will be a very big quarter for us as compared to the previous quarters.

Q&A highlights

8 direct
Swap Ratio and Valuation of Kopran Labs Direct
The valuation exercise was done by EY and Armslength Advisors, and swap ratio was, I think, fairness value swap ratio was done by Saffron Advisors. They have taken all necessary parameters for valuing both the companies arriving at swap ratio. So we have gone with their advice and done as per their valuation reports... Kopran Lab was valued at about INR256 crores and at about INR25 crores of cash, so about INR230 crores.

Clarifies the methodology and specific valuation figures for Kopran Labs, which is central to the merger.

Asked by Maulik Varia

Muted Revenue Growth for Kopran Labs (9M FY25) Direct
So the main quarter for Kopran Laboratories is the last quarter of the year, which is Q4, and that contributes to a bulk of the business of the company because a lot of government tenders, a lot of government orders, etcetera, are closing before 31st of March... So our last quarter was close to a INR43 crores quarter. So similarly, this year as well, we expect that Q4 will be a very big quarter for us as compared to the previous quarters.

Explains the seasonality of Kopran Labs' business, addressing concerns about lower 9-month revenue and setting expectations for a strong Q4.

Asked by Maulik Varia

Nature of Kopran Labs Business (Trading vs. Services) and Margins Direct
So no, this is not a trading business. I mentioned about long-term agreements that we do which form a significant part of our business... So I would not call it a trading business. It is more a services business... So typically, we would like to we would work with -- EBITDA margin is around 28% to 30%.

Clarifies the business model as service-oriented with long-term contracts, not just trading, and provides a clear EBITDA margin target.

Asked by Julie Mehta

Contract Timelines for Machine Placements Direct
No, we do not do such short time lines because naturally, when we are investing in these machines, there is a certain amount of payback... So these are typically around 5 years. Some of them are 4 years, some of them could be 7 years, but typically average is around 5 years - 5.5 years.

Provides insight into the long-term nature of customer relationships and the payback period for machine investments, reinforcing the annuity model.

Asked by Julie Mehta

EPS Accretion and Cost Implications of Marketing Direct
The call for the marketing and what you mentioned, they are already -- Kopran Laboratories is already covering those costs. And so that part is not going to affect in terms of Kopran Limited numbers.

Addresses a potential concern about increased SG&A costs post-merger, clarifying that these costs are already managed by Kopran Labs and won't negatively impact Kopran Limited's EPS.

Asked by Julie Mehta

Kopran Labs Team Strength and Geographic Presence Direct
You mean in terms of people, we have a team of about 75 people... It is all India. We have offices in Delhi, in Calcutta, in Bangalore, obviously, Mumbai as well and satellite offices in few other towns as well.

Provides operational details about the scale and reach of Kopran Labs' sales and service network.

Asked by Hrishikesh Patole

Low-Hanging Fruits and Target Customers Direct
We are only into B2B. We are not into B2C... We do a lot of work with government. So in terms of tender opportunities or if there are any Tier 2 or Tier 3 cities, if there is any upgradation required, that is what we like to target because I think that is an area where the big multinational companies don't focus.

Clarifies the B2B focus and strategic targeting of Tier 2/3 cities and government tenders, differentiating their approach from larger multinationals.

Asked by Hrishikesh Patole

Competitors in the Diagnostics Space Direct
So naturally, there are multinational companies like an Abbott or a Siemens or Roche, for example, these are all companies, European and American companies, which operate in this space. But what I feel we are slightly different because we are brand agnostic. We work with multiple brands.

Identifies key competitors and highlights Kopran Labs' differentiated strategy of being brand-agnostic and working with multiple brands.

Asked by Maulik Varia

3 min read 7 chapters

Detailed narrative

Scheme of Amalgamation and Rationale

Kopran Limited announced the Board approval on March 20, 2025, for the merger of Kopran Laboratories Limited into Kopran Limited. The proposed share exchange ratio is 100 fully paid up equity shares of Kopran Limited for every 45 fully paid up equity shares of Kopran Laboratories Limited, pending regulatory approvals. This merger is expected to create significant synergies by leveraging the strengths of both companies, providing Kopran Limited an entry into the fast-growing Indian diagnostic industry, and ultimately being EPS accretive for Kopran Limited shareholders.

Kopran Laboratories Business Model and Operations

Kopran Laboratories operates in the Indian diagnostics segment, focusing on marketing diagnostic equipment, consumables, and automation products to path labs and hospitals. The business model is primarily service-oriented, not trading, with approximately 50% of its top line coming from long-term contracts. These contracts typically span 5 to 5.5 years, where Kopran Labs invests in hardware and customers commit to purchasing consumables. The company represents about 25 multinational companies for marketing and servicing their products across India, with a team of 75 people and offices in major cities.

Financial Performance and Growth of Kopran Laboratories

Kopran Laboratories reported 9-month revenue of INR 68-69 crores for the current year, compared to INR 59 crores in the previous year. Its FY24 top line reached INR 103 crores, representing a growth of approximately 45% year-on-year. The business exhibits seasonality, with Q4 typically being the strongest quarter due to the closing of government tenders and orders before the financial year-end. Management expects Q4 FY25 to be a 'very big quarter' similar to Q4 FY24, which contributed INR 43 crores to the annual revenue.

Market Opportunity in Indian Diagnostics

The Indian diagnostic industry is a fast-growing sector, currently valued at $14 billion and projected to grow at a CAGR of 14% over the next five years, reaching $25 billion by FY28 and nearly threefold by 2034. Kopran Laboratories primarily operates in the B2B segment, targeting government hospitals, medical colleges, and path labs, particularly in Tier 2 and Tier 3 cities where large multinational companies have less focus. The company also aims to capitalize on its relationships to market Kopran's products into hospitals and government institutions.

Capital Expenditure and Funding Strategy

Kopran Laboratories typically adds 20-25 machines annually, which translates to an annual capital expenditure of INR 7-8 crores. This capex is entirely funded through internal accruals, with Kopran Limited having a 'decent amount of cash' to support these requirements. The company's strategy involves investing in equipment for customers, enabling them to upgrade facilities without significant upfront capital investment, thereby securing long-term consumable purchase agreements.

Post-Merger Strategic Vision and Synergies

The merger will transform Kopran Limited into a comprehensive healthcare company, integrating its existing API and formulations businesses with the diagnostic segment. This integration is expected to create synergies by leveraging Kopran Limited's manufacturing capabilities to repack and manufacture diagnostic kits, thereby increasing margins and profitability. The combined entity plans to explore B2C opportunities in the future and is actively engaging with multinational companies to expand its offerings and market presence in the healthcare industry.

Competitive Landscape and Differentiation

Kopran Laboratories competes with major multinational players such as Abbott, Siemens, and Roche in the diagnostics space. However, Kopran Labs differentiates itself by being 'brand agnostic,' working with multiple brands and offering solutions in areas where larger companies may not have products. Its focus on Tier 2 and Tier 3 cities and government tenders also provides a competitive edge, as these segments are often underserved by larger players.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls